AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Carnitine O-acetyltransferase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P43155

UPID:

CACP_HUMAN

Alternative names:

Carnitine acetyltransferase

Alternative UPACC:

P43155; Q5T952; Q9BW16

Background:

Carnitine O-acetyltransferase, also known as Carnitine acetyltransferase, plays a pivotal role in fatty acid metabolism. It catalyzes the reversible transfer of acyl groups between carnitine and coenzyme A, regulating the acyl-CoA/CoA ratio. This enzyme is essential for transporting fatty acids for beta-oxidation and synthesizes various acylcarnitines, facilitating energy production from fats.

Therapeutic significance:

The enzyme's dysfunction is linked to Neurodegeneration with brain iron accumulation 8, a disorder marked by iron build-up in the brain, leading to severe neurodegenerative symptoms. Understanding Carnitine O-acetyltransferase's role could unveil new therapeutic strategies for treating this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.